Literature DB >> 32030689

CD200-CD200R Pathway in the Regulation of Tumor Immune Microenvironment and Immunotherapy.

Jin-Qing Liu1, Aiyan Hu1,2, Jianmin Zhu1,2, Jianyu Yu1,3, Fatemeh Talebian1, Xue-Feng Bai4.   

Abstract

Tumor-associated inflammation and immune responses are key components in the tumor microenvironment (TME) which regulate tumor growth, progression, and metastasis. Tumor-associated myeloid cells (TAMCs) are a group of cells that play multiple key roles including induction of tumor-associated inflammation/angiogenesis and regulation of tumor-specific T-cell responses. Thus, identification and characterization of key pathways that can regulate TAMCs are of critical importance for developing cancer immunotherapy. Recent studies suggest that CD200-CD200 receptor (CD200R) interaction may be important in regulating the TME via affecting TAMCs. In this chapter, we will give a brief overview of the CD200-CD200R axis, including the biology behind CD200-CD200R interaction and the role(s) it plays in tumor microenvironment and tumor growth, and activation/effector functions of T cells. We will also discuss CD200-CD200R's role as potential checkpoint molecules for cancer immunotherapy. Further investigation of the CD200-CD200R pathway will not only advance our understanding of tumor pathogenesis and immunity but also provide the rationale for CD200-CD200R-targeted immunotherapy of human cancer.

Entities:  

Keywords:  CD200; CD200 receptor; Cytotoxic T lymphocytes (CTLs); Dendritic cells (DCs); Immunotherapy; Myeloid derived suppressor cells (MDSCs); Regulatory T cells (Tregs); Tumor immunity; Tumor microenvironment; Tumor-associated macrophages (TAMs); Tumor-associated myeloid cells (TAMCs)

Mesh:

Substances:

Year:  2020        PMID: 32030689      PMCID: PMC7339106          DOI: 10.1007/978-3-030-35582-1_8

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  61 in total

1.  CD200 as a prognostic factor in acute myeloid leukaemia.

Authors:  A Tonks; R Hills; P White; B Rosie; K I Mills; A K Burnett; R L Darley
Journal:  Leukemia       Date:  2007-01-25       Impact factor: 11.528

2.  Endothelial CD200 is heterogeneously distributed, regulated and involved in immune cell-endothelium interactions.

Authors:  Ya-Chen Ko; Hsiung-Fei Chien; Ya-Fen Jiang-Shieh; Chiu-Yun Chang; Man-Hui Pai; Jian-Pei Huang; Hui-Min Chen; Ching-Hsiang Wu
Journal:  J Anat       Date:  2009-01       Impact factor: 2.610

3.  Lack of CD200 enhances pathological T cell responses during influenza infection.

Authors:  Tomasz P Rygiel; Eva S K Rijkers; Talitha de Ruiter; Ellen H Stolte; Martin van der Valk; Guus F Rimmelzwaan; Louis Boon; Anton M van Loon; Frank E Coenjaerts; Robert M Hoek; Kiki Tesselaar; Linde Meyaard
Journal:  J Immunol       Date:  2009-07-08       Impact factor: 5.422

4.  Further evidence for a role of tumor CD200 expression in breast cancer metastasis: decreased metastasis in CD200R1KO mice or using CD200-silenced EMT6.

Authors:  Anna Podnos; David A Clark; Nuray Erin; Kai Yu; Reginald M Gorczynski
Journal:  Breast Cancer Res Treat       Date:  2012-09-28       Impact factor: 4.872

5.  Increased expression of CD200 on circulating CD11b+ monocytes in patients with neovascular age-related macular degeneration.

Authors:  Amardeep Singh; Mads K Falk; Thomas V F Hviid; Torben L Sørensen
Journal:  Ophthalmology       Date:  2013-02-12       Impact factor: 12.079

Review 6.  Role of tumor-associated macrophages in tumor progression and invasion.

Authors:  Alberto Mantovani; Tiziana Schioppa; Chiara Porta; Paola Allavena; Antonio Sica
Journal:  Cancer Metastasis Rev       Date:  2006-09       Impact factor: 9.264

Review 7.  CD200 and membrane protein interactions in the control of myeloid cells.

Authors:  A Neil Barclay; Gavin J Wright; Gary Brooke; Marion H Brown
Journal:  Trends Immunol       Date:  2002-06       Impact factor: 16.687

Review 8.  Rationale for anti-CD200 immunotherapy in B-CLL and other hematologic malignancies: new concepts in blocking immune suppression.

Authors:  Anke Kretz-Rommel; Katherine S Bowdish
Journal:  Expert Opin Biol Ther       Date:  2008-01       Impact factor: 4.388

Review 9.  Tumour-associated macrophages as treatment targets in oncology.

Authors:  Alberto Mantovani; Federica Marchesi; Alberto Malesci; Luigi Laghi; Paola Allavena
Journal:  Nat Rev Clin Oncol       Date:  2017-01-24       Impact factor: 66.675

10.  CD200 Expression in Neuroendocrine Neoplasms.

Authors:  Jason E Love; Kimberly Thompson; Mark R Kilgore; Maria Westerhoff; Claire E Murphy; Antonios Papanicolau-Sengos; Kinsey A McCormick; Veena Shankaran; Natalie Vandeven; Faith Miller; Astrid Blom; Paul T Nghiem; Steven J Kussick
Journal:  Am J Clin Pathol       Date:  2017-09-01       Impact factor: 2.493

View more
  9 in total

1.  The prognostic value of the advanced lung cancer inflammation index (ALI) for patients with neuroblastoma.

Authors:  Can Qi; Yun Zhou; Zhonghui Hu; Huizhong Niu; Fang Yue; Huibo An; Zhiguo Chen; Ping Wang; Le Wang; Guochen Duan
Journal:  J Int Med Res       Date:  2022-06       Impact factor: 1.573

2.  Immuno-activated mesenchymal stem cell living electrospun nanofibers for promoting diabetic wound repair.

Authors:  Shaoying Gao; Tao Chen; Zhen Wang; Ping Ji; Lin Xu; Wenguo Cui; Ying Wang
Journal:  J Nanobiotechnology       Date:  2022-06-21       Impact factor: 9.429

Review 3.  Neural Stem Cell Transplantation for Neurodegenerative Diseases.

Authors:  Roberta De Gioia; Fabio Biella; Gaia Citterio; Federica Rizzo; Elena Abati; Monica Nizzardo; Nereo Bresolin; Giacomo Pietro Comi; Stefania Corti
Journal:  Int J Mol Sci       Date:  2020-04-28       Impact factor: 5.923

4.  Tumour heterogeneity and intercellular networks of nasopharyngeal carcinoma at single cell resolution.

Authors:  Yang Liu; Shuai He; Xi-Liang Wang; Wan Peng; Qiu-Yan Chen; Dong-Mei Chi; Jie-Rong Chen; Bo-Wei Han; Guo-Wang Lin; Yi-Qi Li; Qian-Yu Wang; Rou-Jun Peng; Pan-Pan Wei; Xiang Guo; Bo Li; Xiaojun Xia; Hai-Qiang Mai; Xue-Da Hu; Zemin Zhang; Yi-Xin Zeng; Jin-Xin Bei
Journal:  Nat Commun       Date:  2021-02-02       Impact factor: 14.919

5.  CD200-CD200R immune checkpoint engagement regulates ILC2 effector function and ameliorates lung inflammation in asthma.

Authors:  Pedram Shafiei-Jahani; Doumet Georges Helou; Benjamin P Hurrell; Emily Howard; Christine Quach; Jacob D Painter; Lauriane Galle-Treger; Meng Li; Yong-Hwee Eddie Loh; Omid Akbari
Journal:  Nat Commun       Date:  2021-05-05       Impact factor: 14.919

6.  CD200 Blockade Modulates Tumor Immune Microenvironment but Fails to Show Efficacy in Inhibiting Tumor Growth in a Murine Model of Melanoma.

Authors:  Fatemeh Talebian; Jianyu Yu; Kimberly Lynch; Jin-Qing Liu; William E Carson; Xue-Feng Bai
Journal:  Front Cell Dev Biol       Date:  2021-10-08

Review 7.  Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity.

Authors:  Adrià Archilla-Ortega; Carla Domuro; Juan Martin-Liberal; Purificación Muñoz
Journal:  J Exp Clin Cancer Res       Date:  2022-02-14

8.  Identification of an autophagy-related gene signature for predicting prognosis and immune activity in pancreatic adenocarcinoma.

Authors:  Jiang Deng; Qian Zhang; Liping Lv; Ping Ma; Yangyang Zhang; Ning Zhao; Yanyu Zhang
Journal:  Sci Rep       Date:  2022-04-29       Impact factor: 4.996

9.  Identification of an Autophagy-Related Pair Signature for Predicting Prognoses and Immune Activity in Pancreatic Adenocarcinoma.

Authors:  Qian Zhang; Liping Lv; Ping Ma; Yangyang Zhang; Jiang Deng; Yanyu Zhang
Journal:  Front Immunol       Date:  2021-12-09       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.